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Abstract
Background: Chordoma is a rare invasive bone tumor that may occur anywhere along the neuraxis. A total of
three primary histological varieties have been identified: conventional, chondroid, and dedifferentiated.
Case presentation: We report a case of an 8-year-old white girl who presented with conventional chordoma, was
treated with surgical resection and mixed proton and photon beam therapy, and had a recurrence in the resection
cavity 2.5 years later with dedifferentiated morphology. The recurrent tumor did not express brachyury, a recently
identified protein specific to tissue of notochordal origin.
Conclusions: The short time period between radiation therapy and dedifferentiation, low dose of photons, and
rarity of dedifferentiated skull base chordomas in pediatric patients should alert clinicians to the possibility of
chordoma dedifferentiation after proton beam therapy.
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Background
Chordoma is a rare, locally invasive bone tumor of noto-
chordal origin with an incidence of 0.1 to 0.8/1,000,000
[1–3]. It is 40 % less likely in females compared to males
[2, 4]. The tumor can present at the base of the skull, in
the vertebral column, or in the sacral region, but there is
controversy over the relative incidence at these sites [2, 5].
Although chordomas are typically a tumor of the aged,
presentation in younger individuals tends to occur at the
skull base [2, 4, 6]. In addition, female gender is associated
with greater likelihood of presentation in the skull
base [2, 4]. The overall median survival after chor-
doma diagnosis is approximately 6 years, but it is
higher for tumors with chondroid histology and lower for
those with dedifferentiated histology compared to the
conventional variety [2, 7].
Skull base chordomas are typically surgically resected
and proton beam therapy is often used to treat residual
tumor [8, 9]. We report the first case, to the best of our
knowledge, of a skull base chordoma that dedifferentiated




An 8-year-old white girl with no family history of skin
cancer except for skin cancer in her grandfather com-
plained of 4 weeks of pressure-like headaches, mostly in
the posterior occipital area, and intermittent nausea with
several episodes of emesis in June of 2012. A physical
examination was significant for decreased sensation to
light touch over the right side of her face and her right
upper extremity. Magnetic resonance imaging (MRI) of
her brain revealed a large heterogeneous skull base mass.
Chordoma was suspected over chondrosarcoma, and the
diagnosis was confirmed by pathology after tissue was ob-
tained during an endonasal surgical resection. Resection
of the chordoma left residual tumor in her lateral skull
base at the hypoglossal canal and jugular foramen. She
was referred to a proton facility where she received frac-
tionated proton and photon beam therapy: 77.4 Gy total,
59.4 Gy (cobalt gray equivalent) in 33 fractions with pro-
tons and 18 Gy in 10 fractions with photons. She was
returned to our care afterwards. Scheduled MRIs showed
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decreasing lesion size through postoperative year 2. How-
ever, she experienced acute cranial nerve 6 palsy approxi-
mately 2.5 years after surgical resection. An MRI showed a
3×1.5×4 cm mass in the resection cavity with signal change
suspicious for dedifferentiation. A subsequent biopsy ob-
tained during a retrosigmoid craniotomy confirmed high-
grade sarcoma. She has since completed 17 cycles of ifosfa-
mide and etoposide alternating with vincristine, doxorubicin,
and cyclophosphamide with the last round in April 2016.
She began maintenance capecitabine on 26 April 2016. The
most recent MRI, approximately 14 months after her second
surgery, showed a mild interval decrease in tumor size.
Imaging findings
MRI of our patient’s brain with and without contrast at her
initial presentation showed a large heterogeneous mass em-
anating intracranially from the base of her clivus and ex-
tending through the foramen magnum to C1–C2. A small
portion was anterior to C1–C2 in her nasopharyngeal soft
tissues with extension through her left hypoglossal canal.
Posteriorly, the lesion displaced her pons and medulla.
Multiple cranial nerves were not well seen and were either
displaced or encased by the mass as it filled the right
cerebellomedullary angle. The lesion was T1 isointense to
muscle (Fig. 1a), and only mildly enhanced in portions
(Fig. 1b). The lesion had a predominantly very bright T2
signal (Fig. 1c). There was restricted diffusion with bright
diffusion-weighted imaging and dark apparent diffusion co-
efficient signals, indicating hypercellularity (Fig. 1d, e).
Follow-up MRI 2.5 years after the initial MRI, and after
surgery and proton beam therapy, showed local recurrence.
The recurrent tumor was centered at the rightward aspect
of her clivus and extended superiorly to the dorsum sella
and inferiorly to the level of the occipital condyle. The
signal intensity of this mass was intermediate to dark, isoin-
tense to gray matter on T2-weighted images in contrast to
the very T2 hyperintense signal like cerebral spinal fluid as
seen on the initial presentation (Fig. 2a). In addition, on
follow-up the lesion was avidly enhancing post-contrast on
T1-weighted imaging (Fig. 2b) as compared to the initial
lesion where there was only mild enhancement.
Pathology findings
The biopsy from the initial lesion showed classic chor-
doma histology with physaliphorous cells with multiva-
cuolated cytoplasm mixed with epithelioid cells arranged
Table 1 Timeline of the patient’s clinical course
Date Event
16 Jun 2012 Initial presentation with headaches and emesis prompts magnetic resonance imaging that shows a large
heterogeneous skull base mass suspicious for chordoma.
2 Jul 2012 Endonasal surgical resection. Surgical pathology confirms chordoma diagnosis.
2 Nov – 29 Nov 2012 Fractionated proton and photon beam therapy: 77.4 Gy total, 59.4 Gy (cobalt gray equivalent) in 33 fractions
with protons and 18 Gy in 10 fractions with photons.
18 Jun – 11 Dec 2013 Interval decrease in tumor size visualized at scheduled magnetic resonance imagings.
3 Jan 2015 Visual disturbances prompt magnetic resonance imaging, which shows an enhancing mass in the resection
site suspicious for recurrence with dedifferentiation.
21 Jan 2015 Retrosigmoid craniotomy. Surgical pathology shows complete dedifferentiation.
29 Mar 2015 Begins ifosfamide and etoposide alternating every 2 weeks with vincristine, doxorubicin, and cyclophosphamide.
23 Apr 2015 – 25 Mar 2016 Interval decrease in tumor size visualized at scheduled magnetic resonance imagings. Continues ifosfamide and
etoposide alternating every 2 weeks with vincristine, doxorubicin, and cyclophosphamide.
26 Apr 2016 Last of 17 cycles of ifosfamide and etoposide alternating with vincristine, doxorubicin, and cyclophosphamide.
Begins maintenance capecitabine.
Fig. 1 a T1-weighted sagittal magnetic resonance imaging showing a lesion isointense to muscle which displaced pons and medulla posteriorly and
with a small nasopharyngeal component (arrow). b Post-contrast axial T1-weighted image showed mild enhancement (arrow). c Axial T2-weighted
magnetic resonance imaging showing bright signal (arrows). d Restricted diffusion with bright diffusion-weighted imaging signal (arrow). e Restricted
diffusion with dark apparent diffusion coefficient signal (arrow)
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in anastomosing cords, clusters, and chains. There was a
myxoid matrix and occasional fibrous septa (Fig. 3). No
immunohistochemical stains were performed as hist-
ology provided a definitive diagnosis.
Hematoxylin and eosin staining of the recurrent tumor
obtained during our patient’s second surgery, however,
showed a high-grade anaplastic spindle cell neoplasm.
There were areas of geographical necrosis with no par-
ticular architectural pattern visible at low magnification
(Fig. 4a). In the higher power images, the cells were very
pleomorphic with epithelioid and spindle shapes, and
there were mitotic figures present (Fig. 4b). Myofibroblastic
tumor and fibrosarcoma, leiomyosarcoma, and rhabdomyo-
sarcoma were ruled out with immunohistochemistry.
Vimentin was positive, consistent with sarcoma in general.
Ki-67, a proliferation index that is normally very low in a
chordoma, was scored at 80 %, indicating rapid cellular div-
ision. Epithelial membrane antigen (EMA), cytokeratin, and
brachyury were negative, indicating full dedifferentiation.
Discussion
Less than 5 % of chordoma diagnoses occur in children
under 10 years of age [2]. Among childhood cases, Borba
and colleagues found a distinct difference in presentation,
tumor morphology, and prognosis between cases occur-
ring in children under and over age 5 [10]. Children under
age 5 frequently have long tract deficits [11, 12] and intra-
cranial hypertension, and the tumor is often of an atypical
morphology, which has a poor prognosis [10]. Children
over age 5 most frequently present with double vision
[13–17] and headaches [13, 18, 19], have typical tumor
morphology, and, thus, survive for longer [10]. Our pa-
tient, an 8-year-old girl presenting with headaches and
nausea, was found to have a typical clival chordoma,
which initially fit the expected pattern of disease presenta-
tion. The histology and imaging appearance of her tumor,
though, changed with recurrence 2.5 years after the initial
surgical resection and radiation therapy.
Chordomas show dual epithelial-mesenchymal differ-
entiation as they arise from embryonic remnants of the
notochord [20]. Although the molecular pathogenesis of
chordoma is not fully known, brachyury has been shown
to be both a regulator of notochordal differentiation and
a chordoma marker. Cytogenetic studies have shown
that mutations on multiple chromosomes are associated
with chordoma [21]. Conventional chordomas feature
large polygonal cells with abundant eosinophilic to
amphophilic cytoplasm, variable nuclei, and occasional
Fig. 2 a Axial T2-weighted image of the recurrent tumor showing intermediate to dark, isointense to gray matter signal intensity (arrow). b Axial
T1-weighted post-contrast image showing avid enhancement (arrow)
Fig. 3 Hematoxylin and eosin stain showing pathognomonic
physaliphorous cells with multivacuolated cytoplasm (arrows), mixed
with epithelioid cells. Nuclei are relatively bland without significant
pleomorphism. Magnification 40×
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vacuoles (physaliferous cells) arranged in cords and sheets
in a myxoid stroma [22, 23]. Chondroid chordomas have
regions where the stroma resembles hyaline cartilage and
neoplastic, sometimes physaliferous, cells grow in lacunae
[22, 23]. Finally, dedifferentiated chordomas have regions
of or have become entirely composed of malignant sar-
comatous cells [22, 24]. Previous reports have shown
possible loss of EMA and cytokeratin [24, 25], but our
case is the first to report absence of brachyury in the
dedifferentiated tumor. In addition, dedifferentiation
was faster than in earlier reports of completely dediffer-
entiated chordoma occurring after conventional radio-
therapy [26, 27].
T1-weighted MRI shows chordomas as having pre-
dominantly intermediate to dark signal [28]. They are
typically bright on T2-weighted MRI, but dedifferen-
tiated chordomas are not [29]. Diffusion-weighted MRI
will show diffusion restriction, but this may be difficult
to interpret in skull base tumors due to artifact at the
skull base [30]. Contrast enhancement is variable [31].
Further advancements in molecular imaging may allow
for definitive diagnosis without the need for biopsy.
Much as immunohistochemistry is used to identify pro-
teins in biopsies, radiolabeled molecular probes and tar-
geted MRI contrasts may be used in the future to
identify unique proteins in neoplasms [32]. Skull base
chordomas most often involve the upper half of the cli-
vus and often extend to the lower half of the clivus, pos-
terior clinoid process, cavernous sinus, and occipital
condyle [30]. Our patient’s tumor showed typical MRI
presentation when she first presented to us. However,
the resection site recurrence had intermediate to dark
signal on T2-weighted images.
Most recent research indicates the overall prognosis
for younger patients is better than for adult patients with
chordoma, although there have been contradictory
findings [3, 4, 23, 30]. Surgical margins are the most
important prognostic indicator for patients without
dedifferentiated chordoma, and gross resection or debulk-
ing is recommended for patients without contraindica-
tions [8]. However, dedifferentiated chordomas are less
responsive to surgery and carry a worse prognosis [8, 33].
Residual tumor in the resection cavity responds best to
high doses of radiation, which creates a difficulty when
treating clival tumors because the adjacent structures are
critical and radiosensitive [8]. Proton beam therapy is used
to deliver high doses of radiation (70 to 80 GyE) with less
damage to non-neoplastic tissue than conventional pho-
ton radiotherapy due to its sharp Bragg peak [9, 34]. How-
ever, side effects such as radiation necrosis of the optic
nerve and temporal lobe, epilepsy, inhibition of the hypo-
thalamic–pituitary axis, and other endocrinopathies have
been reported [8, 34, 35]. Hara and colleagues reported the
only case of a sarcomatoid transformation after proton
beam therapy, which occurred 3 years after the initial treat-
ment and 1 year after a second course of proton beam ther-
apy [36]. It is important to note that some authors
distinguish between sarcomatoid chordoma and dedifferen-
tiated chordoma in that the first retains immunoreactivity
for cytokeratin, whereas the latter does not [24, 37].
Conclusions
Our patient’s case is the first report, to the best of our
knowledge, of a chordoma that dedifferentiated after
protein beam therapy. There are reports of dedifferenti-
ation after conventional radiation therapy, although the
typical photon dose in those cases is severalfold greater
than 18 Gy and disease progression much longer than
2.5 years [27, 38, 39]. The case reported here should
alert clinicians to the possibility of dedifferentiation after
proton beam therapy and prompt histologic analysis of
recurrent tumors in this setting. We did not identify any
other cases of dedifferentiated skull base chordoma in
pediatric patients when reviewing 29 cases published
after Borba and colleagues’ 1996 literature review [10].
This highlights the unusual nature of this presentation
Fig. 4 a Unlike tissue from the first biopsy, the recurrent tumor had prominent areas of necrosis (arrows; 5× magnification). b Mitotic figure
(circled) and nuclear pleomorphism were seen at 40× magnification. Spindle cells were seen, but physaliphorous cells were not noted
Frankl et al. Journal of Medical Case Reports  (2016) 10:280 Page 4 of 6
and the likelihood that proton beam therapy may have
contributed to the tumor’s dedifferentiation.
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